TORONTO, ONTARIO--(Marketwired - Mar 7, 2017) - Canada House Wellness Group Inc. ("Canada House") or the ("Company") (CSE:CHV)(CHV.CN) is pleased to provide an update on its patient initiatives and expansion plans, along with a corporate update.

Patient Initiatives and Expansion

Canada House continues to grow the patient base which it supports with cannabis education and resources. Over the past two months it has developed and streamlined its organizational and administrative processes to keep up with the ongoing demand for quality medical management supporting cannabinoid therapy. These new efficiencies are expected to provide the Company with greater controls resulting in new levels of conversion and retention, thereby increasing revenue.

As Canada House continues along its trajectory of expansion and penetration internal to the medical marijuana marketplace, it has also identified high value revenue channels supplying medical goods and services to the cannabis patient population.

As a result, the Company has begun focusing on growing its clinical division in strategic partnerships with existing clinic networks, in addition to operating its own full spectrum wellness centres and total health clinics.

The underlying premise is that ancillary to cannabis therapy and in support of a patient's health, there are often both physical and non-physical therapies which work in conjunction with cannabinoids for better health outcomes, safety and efficacy.

Canada House has already begun the provision of these products and services both to its Veteran and non-Veteran patients with a robust multi-disciplinary approach, delivered and managed to a high medical standard.

The Company continues to work towards the revenue targets it has set out for the coming periods.

Settlement of Debt

Canada House is also pleased to announce that it has settled certain outstanding debts by the issuance of 753,759 common shares of the Company at a weighted average price of $0.56 per common share. These common shares will be subject to a 4 month trading restriction where applicable. Management expects the settlement of such debts to improve the Company's working capital and liquidity ratios.

Approximately $210,447 of the debt being settled through the issuance of the common shares is owed to a director of a subsidiary of the Company (the "Insider Issuance"). The Insider Issuance constitutes a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Insider Issuance was unanimously approved by the disinterested members of the Company's board of directors. The Company is relying on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement.